MetaCap

Bicara Therapeutics Inc. (BCAX)

NASDAQ: BCAXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.44-0.68 (-7.46%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BCAX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$560.31M
EPS (TTM)
-$3.46
52-week range
7.87 – 30.99
Day range
8.43 – 9.14
Volume / Avg
814.49K / 1.20M
Beta
—

52-week range

$7.87$30.99

BCAX stock today

Shares of Bicara Therapeutics (BCAX) finished lower on Nov 20 at $8.44, a drop of 7.46% or $0.68 per share, versus the S&P 500's 3.70% decline. At this level, BCAX sits near the bottom of its 52-week range of $7.87 to $30.99: 72.8% below the high, set on Jul 7, 2026 and 7.2% above the low. BCAX is down 49.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.2%.

Bicara Therapeutics has posted a net loss over the last twelve months (EPS of -$3.46), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Bicara Therapeutics

Company profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Claire Mazumdar Clemon M.B.A., Ph.D.
Headquarters
Boston, MA
Employees
103
IPO year
2024
Website
bicara.com

Financial highlights

Full financials

Bicara Therapeutics reported a net loss of $137.9 million, compared with a loss of $68.0 million a year earlier. Diluted earnings per share came in at -$2.52.

Bicara Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-137.95M$-68.00M$-51.98M
EPS (diluted)$-2.52$-4.05$-89.61

Analyst forecast

Forecast

Consensus (14 analysts)

strong_buy

Avg. price target

$32.17+281.16%

  • Strong buy 3
  • Buy 10
  • Hold 0
  • Sell 1
  • Strong sell 0

Target range

Low $8.00High $43.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-1.04 vs $-0.84
Surprise
-23.81%

BCAX news

All BCAX news

Bicara Therapeutics peers

Health Care sector
BCAX peer companies
CompanyPrice% ChgMarket capCompare
GERNGeron Corporation0.8707-4.63%$560.94Mvs BCAX
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs BCAX
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs BCAX
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs BCAX
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs BCAX
DSGNDesign Therapeutics Inc.9.02-3.22%$577.61Mvs BCAX
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs BCAX
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs BCAX

Indexes, lists and sector

Bicara Therapeutics stock FAQ

What is Bicara Therapeutics's stock price today?

BCAX last traded at $8.44 as of Nov 20, 4:00 PM EST, down 7.46% on the day. Prices are delayed at least 15 minutes.

Who is Bicara Therapeutics's CEO?

Dr. Claire Mazumdar Clemon M.B.A., Ph.D. is the chief executive officer of Bicara Therapeutics Inc., which has about 103 employees.

What is the BCAX 52-week high?

The 52-week high for BCAX is $30.99 and the 52-week low is $7.87. The stock is currently 72.8% below its high.

Compare BCAX